Syngene International

Bangalore, IN
Biologics Cell Therapy
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-02
81.6
Signal Score
✓ FDA Inspections (1) ○ Clinical Trials ○ SEC Filings ✓ Press (4) ○ EMA GMP ○ MHRA GMP

Quick Facts: Syngene International

Signal Score
81.6/100 (as of 2026-04-02)
Quality Compliance
100.0/100
Headquarters
Bangalore, IN
Modalities
Biologics, Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed — 1 partnership announcement in press
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance 100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-02-20)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs — no verified data
Sponsors— no verified data
ModalitiesBiologics, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 68.0
Parent company: Biocon
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Biocon
Financial assessment: 68.0/100
Capacity 63.0
Regulatory milestones (2 articles)
Sites: Bangalore, IN
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press4 articles
Regulatory milestones (2 articles)

FDA Inspection History

2025-02
NAI VAI OAI
Date Site Type Observations Classification
2025-02-20 Bengaluru Drug Quality Assurance No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Apr 05, 2026

Recent News 4 articles

regulatory 2026-03-20
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 - AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26  AD HOC NEWS
Source →
regulatory 2026-03-20
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26 - AD HOC NEWS
Syngene International stock faces headwinds amid contract research slowdown in Q3 FY26  AD HOC NEWS
Source →
general 2026-03-15
Syngene International Stock (ISIN: INE398A01010) Faces Pressure Amid Biopharma Contract Slowdown - ad-hoc-news.de
Syngene International Stock (ISIN: INE398A01010) Faces Pressure Amid Biopharma Contract Slowdown  AD HOC NEWS
Source →
partnership 2026-02-19
VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure - BioSpace
VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure  BioSpace
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Biologics CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Singota Solutions
Bloomington, IN
Signal Score: 59.0
Cell Therapy, Biologics
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Signal Score: 81.8
mRNA, Biologics, Cell Therapy
Eurofins CDMO
Planegg, DE · San Diego, CA
Signal Score: 81.6
Biologics, Cell Therapy
NegotiumBio LLC & GmbH
Basel, Switzerland (GmbH) / Greater Boston, MA (LLC)
Small Molecules, Biologics, Cell Therapy, Gene Therapy, CAR-T, Viral Vectors, Oligonucleotides
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
Signal Score: 84.2
Biologics